Moderna becomes second manufacturer to announce successful trial results in younger people
Mass vaccination of children against Covid-19 moved a step closer as Moderna became the second manufacturer to announce successful trial results, showing its vaccine can stop transmission in people aged 12 to 18.
Pfizer/BioNTech’s vaccine has already been given emergency approval for adolescents aged 12 to 15 in the United States by the regulator, the Food and Drug Administration (FDA), after its trials were said to show better efficacy even than in ages 16 to 25. It has begun a trial in young children, from six months to 11 years old.
